New combo targets tough lung cancer in early trial
NCT ID NCT07579221
First seen May 15, 2026 · Last updated May 15, 2026
Summary
This early-phase study tests two drugs—navlimetostat and pumitamig—together in people with a certain genetic type of advanced non-small cell lung cancer (MTAP-deficient). The main goals are to find a safe dose and see if the combination shrinks tumors. About 17 adults with measurable disease will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UT MD Anderson
Houston, Texas, 77090, United States
Contact
Contact
Conditions
Explore the condition pages connected to this study.